Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Choudhury on Clinical Trials of Interest in Nonmetastatic CRPC

September 14th 2020

Atish D. Choudhury, MD, PhD, discusses clinical trials of interest examining different agents, such as darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Giri and Gomella on Fostering a New Framework for Genetic Testing Guidelines in Prostate Cancer

September 14th 2020

In our exclusive interview, Dr. Giri and Dr. Gomella discuss the rationale to create the first multidisciplinary, consensus-driven framework for prostate cancer genetic testing, the importance of having a multidisciplinary team weigh in on the recommendations, and key aspects of the guidelines that could have clinical implications for men in this space.

Oncotype DX GPS Test Shows Predictive Benefit in Unfavorable Intermediate-Risk Prostate Cancer

September 14th 2020

Jennifer Cullen, MPH, PhD, discusses the genomic test as a predictor of outcomes in patients with unfavorable intermediate-risk prostate cancer and next steps for research.

Enzalutamide Extends High Health-Related Quality of Life in Metastatic Prostate Cancer

September 9th 2020

The addition of enzalutamide to androgen deprivation therapy (ADT) led to maintained health-related quality of life and low symptom burden versus placebo and ADT in men with metastatic castration-sensitive prostate cancer.

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

September 9th 2020

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Study Analyzes the Role of Genetic Counseling in Men With Prostate Cancer

September 8th 2020

Huma Q. Rana, MD, MPH, discusses a recent trial aimed to identify how genetic counseling could impact an individual’s decision to undergo genetic testing and ultimately, identify strategies to improve access to this service for men with potentially lethal prostate cancer.

AR Inhibition Advances Progress in Metastatic Castration-Sensitive Prostate Cancer Paradigm

September 2nd 2020

Findings from the phase 3 STAMPEDE, LATITUDE , and TITAN studies, brought to light the utility of second-generation androgen receptor inhibitors.

Dr. Nguyen on the Role of Radiation Therapy in High-Risk Prostate Cancer

September 2nd 2020

Paul L. Nguyen, MD, discusses the role of radiation therapy in high-risk prostate cancer.

Rucaparib Shows Meaningful Antitumor Activity in BRCA1/2-Mutated mCRPC

August 28th 2020

Rucaparib (Rubraca) demonstrated encouraging antitumor activity with a manageable safety profile in patients with BRCA-mutant metastatic castration-resistant prostate cancer.

Increased Access to Germline Testing Needed in Prostate Cancer

August 27th 2020

Germline genetic testing is a key component of prostate cancer treatment, and broader testing criteria combined with reduced barriers to these tests could result in better informed care, including preventive surveillance, according to data from a recent study.

Dr. Trinh on the Challenges of the COVID-19 Pandemic in Prostate Cancer

August 26th 2020

Quoc-Dien Trinh, MD, discusses the challenges of the novel coronavirus disease 2019 pandemic in prostate cancer.

Dr. Trinh on How COVID-19 Has Impacted Surgical Decisions in Prostate Cancer

August 26th 2020

Quoc-Dien Trinh, MD, discusses surgical considerations for patients with prostate cancer in light of the novel coronavirus disease pandemic.

COVID-19 Presents New Challenges in the Rapidly Evolving Prostate Cancer Paradigm

August 21st 2020

Bradley A. McGregor, MD, sheds light on recently approved agents, as well as a multitude of novel therapies on the horizon, that appear to spell out a promising future for the treatment of patients with nonmetastatic castration-resistant prostate cancer.

FDA Halts Phase 1 Trial With P-PSMA-101 in mCRPC Following Patient Death

August 18th 2020

The FDA has placed a clinical hold on the phase 1 P-PSMA-101-001 trial examining the autologous CAR T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Taking a Tiered Approach to Prostate Cancer Surgery During the COVID-19 Pandemic

August 18th 2020

Quoc-Dien Trinh, MD, discusses the impact of the COVID-19 pandemic on prostate cancer treatment and factors that are considered to inform treatment decisions.

Cell-Free DNA Analysis Could Aid in Detection, Optimal Management of Resistant Metastatic Prostate Cancer

August 18th 2020

Cell-free DNA–based androgen receptor locus alterations and enhancers correlated with metastatic prostate cancers determined to be resistant to AR-targeted therapies.

Late LHRH Agonists Injections Cause Spike in Testosterone Levels in Prostate Cancer

August 17th 2020

Luteinizing hormone-releasing hormone agonists were found to often be administered later than the scheduled dosing used in patients with prostate cancer on pivotal clinical trials, leading to late testosterone values being greater than 20 ng/dL and the mean testosterone level almost doubling castration level.

Alternative Splicing, E7107 Compound Could Aid in Prostate Cancer Pathogenesis and Drug Development

August 17th 2020

In prostate cancer, investigators have revealed a link between disease progression and the severity of splicing dysregulation, as well as establishing intron retention as an indicator of prostate cancer stemness and aggressiveness.

Biomarker-Driven Monotherapy Enters mCRPC Paradigm

August 15th 2020

The PARP inhibitor olaparib is now available for patients with metastatic castration-resistant prostate cancer whose tumors harbor mutations in homologous recombination repair genes.

Antiandrogens Continue to Be Focus of Nonmetastatic CRPC Treatment

August 12th 2020

Atish D. Choudhury, MD, PhD, sheds light on the nonmetastatic castration-resistant prostate cancer treatment landscape and notable ongoing trials examining antiandrogens in different settings.